Skip to content

Regulation of Platelet Function in Older Patients With Atrial Fibrillation

Regulation of Platelet Function in Older Patients With Atrial Fibrillation

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07724301
Enrollment
50
Registered
2026-07-24
Start date
2026-08-01
Completion date
2028-08-01
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Thrombotic Risk

Keywords

atrial fibrillation, thrombosis, bleeding, elderly over 80, antiplatelet drugs, aspirin, clopidogrel, platelet function

Brief summary

The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation. The main question it aims to answer is: -Is platelet reactivity effectively controlled in patients over the age of 80 diagnosed with atrial fibrillation following the Watchman procedure.

Detailed description

Cardiovascular disease remains the leading cause of death and the risk for morbidity and mortality due to cardiovascular disease is thought to increases with age. Platelets play a key role in cardiovascular disease as their activation is essential for the formation of an arterial thrombus, the precursor to myocardial infarction and stroke. Additionally, thrombosis has been shown to be linked to cardiac pathologies including atrial fibrillation. The link between optimal prevention of thrombosis and limiting the risk associated with increased bleeding has not been fully elucidated. Hence, our understanding of the prothrombotic state of the platelet and thrombotic risk in people over the age of 80 is not well understood. In this study, we evaluate the prothrombotic state of the platelets in patients in the cardiovascular clinic over the age of 80 diagnosed with atrial fibrillation who are taking antiplatelet medications to determine the benefits of these interventions in prevention of thrombotic events, propagation of the risk for atrial fibrillation, and bleeding

Interventions

None listed

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
80 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosed with atrial fibrillation, scheduled for a Watchman Procedure

Exclusion criteria

* Healthy, taking antiplatelet medication

Design outcomes

Primary

MeasureTime frameDescription
Platelet reactivityblood draw will occur prior to Watchman procedure and antiplatelet administration and 90 days following Watchman procedure while patients are taking antiplatelet drugsplatelet reactivity will be measured before and after antiplatelet treatment in patients over 80. Outcomes will include 1) platelet aggregation, 2) integrin activation, 3) alpha and dense granule secretion, 4) T-TAS activation, and 5) TEG.

Contacts

CONTACTMichael Holinstat, PhD
mholinst@med.umich.edu734-764-4046

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026